Research Studies
Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For more than 50 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy. At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.
Choosing to participate in a study is an important personal decision. Are you interested in participating in a study? Talk with your doctor and family members or friends about deciding to join a study.
Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?
Sponsor: Boehringer Ingelheim
Indication: CKD
GFR: 20-90
DETAILS >
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.
Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.
Sponsor: AstraZeneca
Indication: CKD & HTN
GFR: 30-89
Principal Investigator: Ankit Mehta, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease
Sponsor: Vertex
Indication: APOL1-Mediated Proteinuric Kidney Disease
GFR: ≥25 to ≤75
Principal Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier)
Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier)
Sponsor: Alpine Immune Sciences / Vertex
Indication: IgA Nephropathy
GFR: ≥30
Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy
Protocol Name: Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy
Sponsor: Calliditas
Indication: IgA Nephropathy
Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study
Protocol Name: Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study (Improving Shared Decision-Making and Access to Non-Dialytic Treatment for People with Kidney Disease)
Sponsor: PCORI / GWU
Indication: Late Stage CKD
GFR: <20
Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/- V
Protocol Name: Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/- V
Sponsor: Novartis
Indication: Lupus Nephritis
GFR: ≥ 25
Observational Study Protocol – Fabry Disease Registry
Protocol Name: Observational Study Protocol – Fabry Disease Registry
Sponsor: Sanofi-Aventis
Indication: Fabry Disease
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Sponsor: Amgen
Indication: Antineutrophil Cytoplasmic Antibody-Associated (ANCA) Vasculitis (Newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis)
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)
Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Sponsor: Dimerix B
Indication: FSGS
GFR: > 30
Primary Investigator: Kim Rice, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)
Protocol Name: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease
Sponsor: Vertex
Indication: APOL1-Mediated Proteinuric Kidney Disease
Primary Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246